Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Clinical trial NCT02052648 · COMPLETED
Trial details
- NCT number
- NCT02052648
- Sponsor
- NewLink Genetics Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2018-04-18
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.